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The unfolded protein response (UPR) maintains
endoplasmic reticulum (ER) proteostasis through
the activation of transcription factors such as
XBP1s and ATF6. The functional consequences of
these transcription factors for ER proteostasis
remain poorly defined. Here, we describe methodol-
ogy that enables orthogonal, small-molecule-
mediated activation of the UPR-associated tran-
scription factors XBP1s and/or ATF6 in the same
cell independent of stress. We employ transcriptom-
ics and quantitative proteomics to evaluate ER
proteostasis network remodeling owing to the
XBP1s and/or ATF6 transcriptional programs.
Furthermore, we demonstrate that the three ER
proteostasis environments accessible by activating
XBP1s and/or ATF6 differentially influence the
folding, trafficking, and degradation of destabilized
ER client proteins without globally affecting the
endogenous proteome. Our data reveal how the ER
proteostasis network is remodeled by the XBP1s
and/or ATF6 transcriptional programs at the molecu-
lar level and demonstrate the potential for selective
restoration of aberrant ER proteostasis of patho-
logic, destabilized proteins through arm-selective
UPR activation.
INTRODUCTION
One-third of the human proteome is directed to the endoplasmic
reticulum (ER) for partitioning between folding and trafficking
versus ER-associated degradation (ERAD), a decision primarily
dictated by the exact composition of the ER protein homeostasis
(or proteostasis) network (Balch et al., 2008; Braakman and Bul-
leid, 2011; Hartl et al., 2011; McClellan et al., 2005). This parti-
tioning protects the integrity of downstream proteomes byCensuring that only folded, functional proteins are trafficked
from the ER (Brodsky and Skach, 2011; Smith et al., 2011b;
Wiseman et al., 2007).
The folding, trafficking, and degradation capacity of the ER is
dynamically adjusted to meet demand by the unfolded protein
response (UPR)—a stress-responsive signaling pathway
comprising three integrated signaling cascades emanating
from the ER transmembrane proteins IRE1, ATF6, and PERK
(Schro¨der and Kaufman, 2005; Walter and Ron, 2011). UPR
signaling is activated by the accumulation of misfolded or aggre-
gated proteins within the ER lumen. UPR activation causes tran-
sient, PERK-mediated translational attenuation and activation
of the basic leucine zipper transcription factors ATF4, XBP1s,
and the cleaved N-terminal fragment of ATF6 downstream of
the ER stress sensors PERK, IRE1, and full-length ATF6, respec-
tively. These transcription factors increase expression of distinct
but overlapping sets of genes comprising both ER-specific and
general cellular proteostasis pathways (Adachi et al., 2008; Lee
et al., 2003; Okada et al., 2002; Yamamoto et al., 2004, 2007).
The three mechanistically distinct arms of the metazoan UPR
presumably evolved to provide cells with flexibility to adapt to
tissue-specific environmental and metabolic demands, creating
a mechanism to restore ER proteostasis in response to a wide
array of cellular insults (Gass et al., 2008; Harding et al., 2001;
Kaser et al., 2008; Wu et al., 2007).
Pharmacologic activation of the UPR offers the potential to
adapt ER proteostasis and rescue misfolded, aberrantly
degraded, or aggregation-prone ER client proteins without
significantly affecting the healthy, wild-type proteome (Balch
et al., 2008; Walter and Ron, 2011). For example, activation of
a UPR signaling pathway that increases ER protein folding ca-
pacity could decrease the aberrant ERAD and increase the ER
folding and export of destabilized, mutant proteins, thereby
ameliorating loss-of-function diseases such as cystic fibrosis
or lysosomal storage diseases (Chiang et al., 2012; Mu et al.,
2008; Wang et al., 2006). Alternatively, increasing ERAD activity
could attenuate the secretion of destabilized, aggregation-prone
proteins that undergo concentration-dependent extracellular
aggregation into amorphous aggregates and amyloid fibrils
(Braakman andBulleid, 2011; Brodsky and Skach, 2011; Luheshiell Reports 3, 1279–1292, April 25, 2013 ª2013 The Authors 1279
Figure 1. Orthogonal, Ligand-Dependent Control of XBP1s and ATF6 Transcriptional Activity
(A) Model illustrating the TMP-mediated, posttranslational regulation of DHFR.ATF6.
(B) Immunoblot of nuclear (top) and postnuclear (bottom) fractions fromHEK293T-REx cells expressingDHFR.YFP or DHFR.ATF6 treated 12 hrwith TMP (10 mM).
The immunoblot of matrin-3 shows the efficiency of the nuclear extraction.
(C) qPCR analysis ofHyou1,HerpUD, and Erdj4 in HEK293T-REx cells expressing DHFR.YFP or DHFR.ATF6 following a 12 hr treatment with TMP (10 mM) or a 6 hr
treatment with Tm (10 mg/ml). qPCR data are reported relative to vehicle-treated cells expressing DHFR.YFP. qPCR data are reported as the mean ± 95%
confidence interval.
(D) TMP dose dependence of HerpUD upregulation in HEK293T-REx cells expressing DHFR.ATF6 (12 hr treatments with TMP). qPCR data are reported as the
mean ± 95% confidence interval.
(legend continued on next page)
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and Dobson, 2009; Sitia and Braakman, 2003), providing a po-
tential strategy to ameliorate amyloid disease pathology.
Concomitant pharmacologic activation of the PERK, IRE1,
and ATF6 UPR arms can be achieved by the application of toxic
small molecules such as tunicamycin (Tm; inhibits protein
N-glycosylation) or thapsigargin (Tg; disrupts ER calcium ho-
meostasis) that induce ER protein misfolding and aggregation,
ultimately causing apoptosis (Schro¨der and Kaufman, 2005;
Walter and Ron, 2011). These global UPR activators have
proven useful for delineating the molecular underpinnings of
UPR signaling pathways. Unfortunately, the pleiotropic effects
and acute toxicity of global UPR activation complicate studies
focused on understanding how UPR activation (either global
or arm selective) remodels the ER proteostasis network in the
absence of an acute ER stress or how the partitioning between
folding and trafficking versus degradation of ER client proteins
can be influenced by arm-selective UPR activation. Thus,
despite the considerable effort focused on understanding the
signaling mechanisms of IRE1, ATF6, and PERK activation,
the functional implications of activating these pathways on ER
proteostasis pathway composition and function remain poorly
defined.
Herein, we introduce small molecule-regulated, genetically
encoded transcription factors that enable orthogonal activation
of UPR transcriptional programs in the same cell. Using our
methodology, we characterize the three distinct ER proteostasis
environments accessible by activating XBP1s and/or ATF6 to
physiologically relevant levels in the absence of stress. We
also evaluate the functional consequences of activating
XBP1s and/or ATF6 on the folding and trafficking versus degra-
dation of destabilized ER client proteins, including transthyretin
(TTR). Ultimately, we demonstrate that arm-selective UPR
activation selectively reduces secretion of a destabilized,
aggregation-prone TTR variant without affecting the analogous
wild-type protein and without globally altering the endogenous
intracellular or secreted proteomes. Our results demonstrate,
in molecular detail, how the XBP1s and/or ATF6 transcriptional
programs integrate to adapt ER proteostasis pathways and
highlight the capacity of functionally distinct ER proteostasis en-
vironments accessed by arm-selective UPR activation to
restore the aberrant ER proteostasis of destabilized protein
variants.
RESULTS
To characterize the ER proteostasis environments accessible by
the selective or combined activity of the UPR-associated tran-
scription factors XBP1s and ATF6, we required methodology
for the small molecule-mediated, orthogonal regulation of two
transcription factors in the same cell. Tetracycline (tet)-repressor
technology can be applied to allow doxycycline (dox)-dependent(E) qPCR analysis of the ATF6 target gene BiP in HepG2, Huh7, or primary fibro
adenoviruses and treated for 12 hr with 100 mM TMP or vehicle. qPCR data are
reported as the mean ± 95% confidence interval.
(F) qPCR analysis of BiP and Erdj4 in HEK293DAX cells following a 12 hr activatio
reported relative to vehicle-treated HEK293DYG cells. qPCR data are reported as
See also Figure S1 and Table S4.
Ccontrol of XBP1s levels in the physiologic range (Lee et al., 2003).
However, we have found that tet-repressor regulation of ATF6
activity within the physiologically relevant range is difficult.
Even after careful optimization and single-colony stable cell se-
lection of HEK293T-REx cells expressing constitutively active
ATF6(1–373) (henceforth termed ATF6) under the tet repressor,
we observed nonphysiologic levels of ATF6 target gene expres-
sion and significant off-target effects including strong upregula-
tion of established XBP1s target genes, following ATF6 induction
at all permissive dox doses (Figures S1A and S1B). We required,
therefore, an alternative strategy to regulate the ATF6 transcrip-
tion factor that would be dosable and orthogonal to tet-repressor
technology.
We envisioned that destabilized domain (DD) technology (Fig-
ure 1A) (Banaszynski et al., 2006; Iwamoto et al., 2010) could be
adapted to prepare a dose-dependent, ligand-regulated ATF6
transcription factor whose activity would be inducible to levels
more consistent with those observed in human physiology. We
fused a destabilized variant of E. coli dihydrofolate reductase
(DHFR) to the N terminus of ATF6 via a short Gly-Ser linker.
The poorly folded DHFR domain directs the entire constitutively
expressed DHFR.ATF6 fusion protein to rapid proteasomal
degradation. Administration of the DHFR-specific pharmaco-
logic chaperone, trimethoprim (TMP), stabilizes the folded
DHFR conformation, increasing the initially poorly populated
folded DHFR population, attenuating proteasomal degradation,
and inducing the ATF6 transcriptional program (Figure 1A).
The addition of TMP stabilizes DHFR.ATF6 in nuclear fractions
isolated from HEK293T-REx cells expressing DHFR.ATF6 (Fig-
ure 1B). DHFR.ATF6 is not detected in the absence of TMP.
Furthermore, TMP induces expression of the ATF6 target genes
HerpUD and Hyou1 (Adachi et al., 2008) in cells expressing
DHFR.ATF6 to levels consistent with those observed following
global UPR-dependent activation induced by Tm (Figure 1C).
We observe no increased expression of these genes in untreated
cells expressing DHFR.ATF6 or TMP-treated cells expressing
DHFR.YFP. The TMP-dependent activation of DHFR.ATF6 is
rapid, causing significant upregulation of HerpUD in <2 hr (Fig-
ure S1C). Importantly, TMP treatment does not induce expres-
sion of the XBP1s-selective target gene Erdj4 (Lee et al., 2003)
(Figure 1C). Increasing concentrations of TMP reveal a linear
dose-dependent upregulation of ATF6 target genes, demon-
strating a significant dynamic range for activation of DHFR.ATF6
by TMP (Figure 1D). Because DHFR.ATF6 is a single gene prod-
uct, it similarly enables the straightforward, ligand-dependent
activation of the ATF6 transcriptional program at physiologic
levels in a wide variety of other cellular model systems
(Figure 1E).
In order to activate both XBP1s and ATF6 in the same cell, we
incorporated DHFR.ATF6 and tet-inducible XBP1s into a
HEK293T-REx cell line stably expressing the tet repressor.blast cells transiently transduced with DHFR.YFP- or DHFR.ATF6-expressing
reported relative to the corresponding vehicle-treated cells. qPCR data are
n of XBP1s (dox; 1 mg/ml), DHFR.ATF6 (TMP; 10 mM), or both. qPCR data are
the mean ± 95% confidence interval.
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Selection of a single colony resulted in the HEK293DAX cell line in
which XBP1s is induced by dox, and DHFR.ATF6 is activated by
TMP (TMP-dependent DHFR.ATF6 activation in HEK293DAX
cells will henceforth be referred to as ATF6 activation for
simplicity). We confirmed ligand-dependent regulation of
XBP1s and ATF6 by immunoblotting (Figure S1D). qPCR anal-
ysis of HEK293DAX cells demonstrates the orthogonal, ligand-
dependent activation of the XBP1s and/or ATF6 transcriptional
programs (Figures 1F and S1E) (Lee et al., 2003). An analogous
HEK293DYG control cell line expressing tet-inducible EGFP and
DHFR.YFP was also prepared as a control (Figure S1D).
The addition of activating ligands to HEK293DAX cells neither
alters the incorporation of [35S]-labeled methionine into the
cellular proteome (Figures S1F and S1G) nor increases eIF2a
phosphorylation (Figure S1H), demonstrating that selective
XBP1s and/or ATF6 activation within the physiologically relevant
regime does not cause PERK-mediated translational attenuation
through stress-induced global UPR activation. Independent acti-
vation of XBP1s or ATF6 also does not significantly reduce
cellular viability (unlike global UPR activators such as Tm or
Tg; Figure S1I). Thus, HEK293DAX cells enable orthogonal control
of the transcriptional programs regulated by XBP1s and ATF6 in
the same cell independent of stress.
Transcriptional andProteomic Profiling of XBP1s and/or
ATF6 Activation in the Same Cell
We assessed changes in the transcriptome of HEK293DAX cells
following activation of XBP1s and/or ATF6 using Affymetrix
whole-genome arrays. Defining a false discovery rate (FDR)
<0.05, XBP1s activation increases the expression of 180 genes,
ATF6 activation increases the expression of 41 genes, and
activation of both XBP1s and ATF6 increases the expression of
351 genes (a smaller number of genes are modestly downregu-
lated; see Table S1). Importantly, the addition of TMP and dox to
HEK293DYG cells did not induce these genes (Table S1). Gene
sets transcriptionally induced by XBP1s and/or ATF6 are highly
enriched for proteins localized to the ER and involved in proteo-
stasis (see Table S2) (Wu et al., 2008; Zhou et al., 2005).
The activation of XBP1s or ATF6 results in the upregulation of
overlapping but divergent gene sets (Figure 2A), reflecting two
distinct ER proteostasis environments accessible by activating
these transcription factors independently. The transcriptionalFigure 2. Transcriptional and Proteomic Profiling of Stress-Independe
Data derived from Affymetrix whole-genome arrays and SILAC-MuDPIT whole-ce
(dox; 1 mg/ml), DHFR.ATF6 (TMP; 10 mM), or both. Only genes with a FDR <0.05
(A) Plot depicting mRNA fold increase owing to XBP1s activation versus ATF6 a
induced by XBP1s (red), ATF6 (blue), or lacking selectivity (purple). Only genes u
(B) Plot depicting a ratio-of-ratios comparison to identify genes cooperatively in
R1.33-fold by the combined activation of XBP1s and ATF6 relative to activating
(C) qPCR analysis validating select genes cooperatively upregulated by the comb
to vehicle-treated HEK293DAX cells. Error bars indicate SE from biological replica
(D–F) Plots of log2 fold change versus log FDR for all proteins identified in our SILAC
in (D) and (E) were calculated from ANOVA p values. FDRs in (F) were calculated
(G–I) Plots of fold change in microarray experiments versus fold change in prote
ATF6, or (I) both. In each panel, the significance of the SILAC-MuDPIT quantifica
(J) Quantification of autoradiograms of media from HEK293DAX cells collected
employed is shown. Error bars represent SE from biological replicates (n = 3).
See also Tables S1 and S3.
Ctargets induced by XBP1s or ATF6 largely overlap with those
previously identified by Adachi et al. (2008), Lee et al. (2003),
Okada et al. (2002), and Yamamoto et al. (2004, 2007). Interest-
ingly, activating both XBP1s and ATF6 affords a third, previously
inaccessible, ER proteostasis environment that is not simply the
sum of the transcriptional consequences of activating XBP1s or
ATF6 independently. This third ER proteostasis environment in-
cludes genes upregulated to similar levels by activating either
XBP1s or ATF6 in comparison to the combination (Figure 2B,
red and blue, respectively). In addition, 31 genes display cooper-
ative upregulation owing to combined XBP1s and ATF6 activa-
tion (Figure 2B, green). We have validated the cooperative
induction of several of these genes by qPCR (Figure 2C). This
cooperative induction likely reflects the binding of both XBP1s
and ATF6 to promoter regions or the preferential binding of
XBP1s/ATF6 heterodimers to select promoters (Yamamoto
et al., 2007) and represents a unique transcriptional profile only
accessible by our ability to activate both XBP1s and ATF6 in
the same cell independent of stress.
To characterize proteome remodeling upon XBP1s and/or
ATF6 activation, we applied quantitative proteomics using Sta-
ble Isotope Labeling by Amino Acids in Cell Culture (SILAC)-
Multi-Dimensional Protein Identification Technology (MuDPIT)
(Ong et al., 2002; Washburn et al., 2001). The conditions used
were identical to those employed in our transcriptome analyses
(see Extended Experimental Procedures for details). Select data
are reported in Table 1, and the complete proteomic data set is
provided in Table S3.
SILAC-MuDPIT analysis demonstrates that activation of
XBP1s and/or ATF6 does not significantly influence the vast
majority of the proteins that comprise the cellular proteome (Fig-
ures 2D–2F). Rather, most proteins significantly upregulated by
activation of XBP1s and/or ATF6 are transcriptional targets of
XBP1s, ATF6, or both (Figures 2G–2I; Table 1). We used quanti-
tative immunoblotting to confirm the increased protein levels for
selected proteins shown to be increased by SILAC-MuDPIT
quantification and for specific ER proteostasis network path-
ways underrepresented in our SILAC-MuDPIT analyses (Table 1;
Figures S2A and S2B). Comparison of the fold change observed
in mRNA levels with that in protein levels demonstrates a quali-
tative correlation between mRNA and protein levels, with the
fold change in transcript levels being generally higher than atnt XBP1s and/or ATF6 Activation in HEK293DAX Cells
ll proteomic analyses of HEK293DAX cells following a 12 hr activation of XBP1s
are described (n = 3), unless otherwise indicated.
ctivation. Dashed lines indicate a 1.9-fold filter to assign genes as selectively
pregulatedR1.5-fold are colored.
duced by XBP1s and ATF6. Genes colored green are cooperatively induced
either transcription factor individually.
ination of XBP1s and ATF6 in HEK293DAX cells. qPCR data are reported relative
tes (n = 3). ***p < 0.005.
-MuDPIT analysis following activation of (D) XBP1s, (E) ATF6, or (F) both. FDRs
using p values from t test distributions.
omics experiments for HEK293DAX cells following activation of (G) XBP1s, (H)
tion is indicated by shading.
after a 4 hr chase in nonradioactive media. The metabolic-labeling protocol
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Table 1. Characterization of XBP1s- and/or ATF6-Remodeled ER Proteostasis Environments
Protein
Fold Change in Arraysa Fold Change in Proteomicsb,c
XBP1s ATF6 Both XBP1s ATF6 Both
ER Import
Sec61A1 2.14 NS 1.95 ND ND ND
SRPR 1.98 NS 1.84 NS NS NS
SRPRB 1.99 NS 1.86 2.1 NS 1.7
SRP19 2.43 NS 2.11 NS NS NS
Hsp40/70/90
GRP78 (BiP) NS 2.24 2.30 1.6 (1.6) 4.1 (4.5) 3.9 (4.5)
GRP94 NS NS 1.26 1.3 (2.0) 2.3 (4.7) 2.2 (4.1)
P58/IPK 2.34 2.36 3.26 NS 1.5 2.2
ERDJ3 1.51 1.94 1.91 ND (1.3) ND (1.2) ND (1.5)
ERDJ4 4.89 NS 5.07 ND ND ND
ERDJ5 1.69 NS 1.92 NS NS 1.8
HYOU1 3.37 4.64 6.32 1.7 (1.7) 2.5 (2.0) 3.1 (2.6)
N-Glycosylation and Lectin-Assisted Folding
STT3A 1.80 NS 1.75 NS NS NS
DDOST NS NS NS 1.3 NS NS
RPN1 1.64 NS 1.76 1.4 NS 1.2
CANX 1.21 NS 1.29 1.2 NS NS
CRT 1.38 2.22 2.09 1.2 1.6 1.6
LMAN1 (ERGIC53) 1.66 NS 1.52 1.7 NS 1.5
Disulfide Redox
PDIA3 (ERP57) 1.62 1.76 1.80 1.2 1.2 1.3
PDIA4 2.74 4.57 4.32 1.7 3.0 3.1
PDIA6 1.62 NS 1.98 1.3 1.4 1.4
ERO1L NS 1.28 1.38 NS NS 1.2
ERO1LB 2.78 2.13 3.44 ND ND ND
Quality Control and Degradation
EDEM1 NS NS 4.18 ND (1.4) ND (0.9) ND (2.5)
EDEM2 2.08 NS 2.13 ND ND ND
EDEM3 1.76 NS 1.82 ND ND ND
DERLIN2 NS NS 2.76 ND ND ND
SYVN1 (HRD1) 2.07 NS 2.67 ND ND ND
VCP (p97) NS NS 1.77 1.3 1.3 1.3
HERPUD1 4.19 8.27 8.62 ND ND ND
XTP3B 2.27 NS 2.32 ND (1.6) ND (1.0) ND (1.9)
OS9 NS 1.60 2.15 ND (0.9) ND (1.6) ND (1.6)
SEL1L 1.76 4.36 4.32 NS NS 2.0
Anterograde Trafficking/Golgi
SEC23B 1.77 NS 1.71 1.6 NS 1.5
SEC24D 5.48 NS 5.60 NS (3.7) NS (0.9) NS (3.1)
SEC31A 2.05 NS 2.60 NS NS 2.0
GOLGB1 1.86 NS 1.81 1.6 NS 1.5
Miscellaneous
DDIT3 (CHOP) NS NS 2.67 ND ND ND
WIPI1 3.14 3.61 5.71 ND ND ND
MSTO1 NS NS 4.63 ND ND ND
(Continued on next page)
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Table 1. Continued
Protein
Fold Change in Arraysa Fold Change in Proteomicsb,c
XBP1s ATF6 Both XBP1s ATF6 Both
SULF1 2.83 NS 5.17 ND ND ND
CRELD2 3.07 4.80 8.04 ND ND ND
NS, not significant; ND, not detected.
aFDR <0.05.
bFDR <0.1.
cQuantity in parentheses is from immunoblotting (see also Figure S2).the protein level (Figures 2G–2I). Thus, combined microarray
and quantitative proteomic characterization of ER proteostasis
pathways in HEK293DAX cells more accurately reflects the
impact of activating XBP1s and/or ATF6 on the molecular
composition of the ER proteostasis network than does transcrip-
tomics alone.
Remodeling the ER proteostasis network through activation of
these transcription factors could have an impact on the secretion
of endogenous, wild-type proteins to the extracellular space.
Interestingly, we found that there was no significant difference
in the accumulation of [35S]-labeled proteins in the extracellular
space following activation of XBP1s and/or ATF6 (Figures 2J
and S2C). These findings strongly suggest that activating
XBP1s and/or ATF6 does not posttranscriptionally alter either
the composition of the intracellular proteome or the folding and
trafficking of endogenous, wild-type proteins through the secre-
tory pathway, although we cannot conclusively rule out alter-
ations in the secretion of low-abundance proteins that are not
detected in our SILAC-MuDPIT or [35S]-labeling experiments.
Integration of Transcriptomics and Proteomics Reveals
Three Distinct ER Proteostasis Environments
Accessible upon Activation of XBP1s and/or ATF6
Our transcriptional and proteomic profiling of HEK293DAX cells
reveals how the composition of the ER proteostasis network is
differentially remodeled by activation of the XBP1s and/or
ATF6 transcriptional programs (Figure 3). Consistent with the
IRE1-XBP1s signaling cascade being the only UPR pathway
conserved from yeast to humans, XBP1s activation has a
broader impact on the composition of ER proteostasis pathways
than does ATF6. XBP1s activation upregulates entire ER
proteostasis pathways, including those involved in ER protein
import, N-linked glycosylation, and anterograde/retrograde
vesicular trafficking (Figure 3, red). The induction of these path-
ways is similarly observed by enrichment analysis (Table S2). In
contrast, although ATF6 is responsible for upregulating only a
select subset of ER proteostasis network proteins, these
ATF6-selective targets represent critical hub proteins in the
ER proteostasis network, including BiP, Sel1L, and calreticulin
(Figure 3, blue).
Some proteins are upregulated to similar levels by activating
XBP1s in isolation, ATF6 in isolation, or both XBP1s and ATF6
(Figure 3, purple). Alternatively, a number of proteins primarily
involved in ER quality control and degradation are cooperatively
upregulated when both XBP1s and ATF6 are activated (Figure 3,
green). These results are consistent with the biological pathwaysCpredicted to be transcriptionally enhanced by XBP1s:ATF6 het-
erodimers (Yamamoto et al., 2007) and clearly demonstrate that
the impact of the combined activation of XBP1s and ATF6 on the
composition of the ER proteostasis network is greater than the
sum of activating XBP1s or ATF6 individually.
Selective Activation of the XBP1s and/or ATF6
Transcriptional Programs Differentially Influences the
Degradation of Null Hong Kong a1-Antitrypsin Variants
To evaluate the functional consequences of activating XBP1s
and/or ATF6 on the degradation of terminally misfolded ER client
proteins, we employed the nonsecreted ERAD substrate null
Hong Kong a1-antitrypsin (NHK-A1AT) (Christianson et al.,
2008) and [35S]-metabolic labeling (Figures 4A–4C). XBP1s acti-
vation increases the rate of NHK-A1AT degradation. Activation
of ATF6 has the opposite effect—resulting in a small but statisti-
cally significant delay in NHK-A1AT degradation (also observed
by cycloheximide chase experiments; see Figure S3A). The
effect of activating both XBP1s and ATF6 on NHK-A1AT degra-
dation is similar to that observed for activation of XBP1s alone.
Notably, we observed no significant impact on NHK-A1AT
degradation in HEK293DYG cells using the same experimental
conditions (Figure S3B). Thus, XBP1s and ATF6 activation
have distinct impacts on NHK-A1AT degradation, consistent
with their differing transcriptional adaptations of the ER proteo-
stasis network (Figure 3).
Stress-independent transcriptional remodeling of the ER
proteostasis environment to enhance the clearance of terminally
misfolded proteins is likely to be client dependent. Because
proteostasis network interactions with NHK-A1AT are primarily
mediated by glycan-binding lectins (Christianson et al., 2008),
removing the three N-linked glycans in the NHK-A1AT structure
by mutating glycosylated asparagines to glutamines changes
the ER proteostasis pathways traversed by NHK-A1AT and,
thus, could alter the consequences of arm-specific UPR activa-
tion for NHK-A1AT degradation. We found that XBP1s activation
moderately enhances degradation of the nonglycosylated
NHK-A1ATQQQ variant, whereas ATF6 activation dramatically
increases the degradation rate of NHK-A1ATQQQ (Figures 4D–
4F). Activating both XBP1s and ATF6 further increases the rate
of NHK-A1ATQQQ degradation (Figures 4D–4F). As in the case
of NHK-A1AT, we observed no significant impact on NHK-
A1ATQQQ degradation in HEK293DYG cells using the same
experimental conditions (Figure S3C). Clearly, the NHK-A1AT
and NHK-A1ATQQQ degradation pathways are uniquely affected
by arm-selective UPR activation, reflecting discrete,ell Reports 3, 1279–1292, April 25, 2013 ª2013 The Authors 1285
Figure 3. Predictive Pathway Analysis for Stress-Independent XBP1s- and/or ATF6-Mediated Remodeling of the ER Proteostasis Network
Cartoon depicting the impact of activating XBP1s, ATF6, or both XBP1s and ATF6 on the composition of ER proteostasis pathways obtained by integrating
transcriptional, proteomic, and biochemical results. XBP1s (red) and ATF6 (blue)-selective genes are genes where activating either XBP1s (but not ATF6) or ATF6
(but not XBP1s) independently results in >75% of the induction observed when both XBP1s and ATF6 are activated (‘‘max induction’’). Genes induced >75% of
the max induction by activating XBP1s in isolation and induced >75% of the max induction by activating ATF6 in isolation (i.e., lacking selectivity) are colored
purple. Genes cooperatively induced >1.33-fold upon activation of both XBP1s and ATF6 relative to the activation of either transcription factor alone are colored
green. Plain type indicates results from array data. Italicized type indicates results from proteomics data. Underlined type indicates results confirmed at both the
transcript and the protein levels. Thresholds for transcriptional analyses were set at a FDR of <0.05. Thresholds for proteomic analyses were set at a FDR of 0.1.substrate-specific functional differences between the ER pro-
teostasis environments illustrated in Figure 3.
Activation of the ATF6 Transcriptional Program
Reduces Secretion of Destabilized Amyloidogenic TTR
Variants without Affecting Wild-Type TTR
We speculated that arm-selective UPR activation could provide
a means to selectively reduce the secretion of destabilized pro-
teins because quality control and degradation are differentially
regulated by the three accessible proteostasis environments
(Figure 3). To test this hypothesis, we evaluated the secretion
of the destabilized, aggregation-prone A25T TTR (FTTTRA25T)
variant (Sekijima et al., 2005) in HEK293DAX cells using [35S]-
metabolic labeling.
FTTTRA25T secretion is decreased 40% following activation
of the ATF6 transcriptional program but is unaffected by
XBP1s activation (Figures 5A and 5B). Activating both XBP1s
and ATF6 decreases FTTTRA25T secretion to a level identical to
that observed for ATF6 activation alone. The ATF6-dependent
decrease in FTTTRA25T secretion is also observed by quantitative
immunoblotting (Figure S4A). FTTTRA25T secretion is not sensi-1286 Cell Reports 3, 1279–1292, April 25, 2013 ª2013 The Authorstive to treatment with dox, TMP, or both in HEK293DYG cells (Fig-
ure S4B). The decrease in FTTTRA25T secretion observed upon
ATF6 activation is similar to that observed upon Tg-dependent
global UPR activation (Figure S4C). Arm-selective ATF6 activa-
tion, however, avoids the negative consequences of a concom-
itant decrease in cell viability caused by global UPR activation
(Figure S1I). The effects of ATF6 are selective for destabilized
TTR variants because FTTTRA25T secretion is selectively reduced
relative to FTTTRWT following ATF6 activation, as measured by
either pulse-chase (Figure 5C) or quantitative immunoblotting
(Figure S4A). A 50% decrease in TTRA25T concentration dramat-
ically reduces its rate and extent of aggregation at pH 6.0
(Figure S4D) (Sekijima et al., 2003). Thus, ATF6-dependent
reductions in mutant TTR secretion would likely attenuate extra-
cellular, concentration-dependent mutant TTR aggregation.
ATF6 activation also leads to a significant decrease in total
[35S]-labeledFTTTRA25T relative to vehicle-treated controls (Fig-
ure 5D). This decrease in total FTTTRA25T cannot be attributed
to increased intracellular TTR aggregation because only 10%
of intracellular TTR is found in detergent-insoluble pellets, and
this fraction is not significantly affected by ATF6 activation
Figure 4. XBP1s and/or ATF6 Activation Differentially Influences the Degradation of NHK-A1AT and NHK-A1ATQQQ
(A) Representative autoradiogram of [35S]-labeled NHK-A1AT immunopurified from transfected HEK293DAX cells following a 15 hr preactivation of XBP1s
(dox; 1 mg/ml), DHFR.ATF6 (TMP; 10 mM), or both. The metabolic-labeling protocol employed is shown.
(B) Quantification of autoradiograms in (A) monitoring the degradation of [35S]-labeled NHK-A1AT. The fraction of NHK-A1AT remaining was calculated by
normalizing the recovered [35S] signal to the total amount of labeling observed at 0 hr. Error bars represent SE from biological replicates (n = 18).
(C) Bar graph depicting the normalized fraction of NHK-A1AT remaining at 3 hr calculated as in (B).
(D) Representative autoradiogram of [35S]-labeled NHK-A1ATQQQ immunopurified from transfected HEK293DAX cells following a 15 hr preactivation of XBP1s
(dox; 1 mg/ml), DHFR.ATF6 (TMP; 10 mM), or both. The metabolic-labeling protocol employed is shown.
(E) Quantification of autoradiograms in (D) monitoring the degradation of [35S]-labeled NHK-A1ATQQQ. The fraction of NHK-A1ATQQQ remaining was calculated as
in (B). Error bars represent SE from biological replicates (n = 6).
(F) Bar graph depicting the normalized fraction of NHK-A1ATQQQ remaining at 4.5 hr calculated as in (B).
*p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S3.(Figure S4E). Intracellular levels of the nonsecreted, highly
destabilized TTR variant FTTTRD18G are similarly decreased
following ATF6 activation relative to controls (Figures S4F and
S4G), suggesting that the observed decrease in mutant TTRCcan be attributed to increased degradation. Consistent with
this prediction, the ATF6-dependent decrease in FTTTRD18G pro-
tein levels is attenuated by the proteasome inhibitor MG-132
(Figure S4G).ell Reports 3, 1279–1292, April 25, 2013 ª2013 The Authors 1287
Figure 5. ATF6 Activation Selectively Attenuates the Secretion of Amyloidogenic TTR
(A) Autoradiogram of [35S]-labeled FTTTRA25T immunopurified frommedia and lysates collected from transfected HEK293DAX cells following a 15 hr preactivation
of XBP1s (dox; 1 mg/ml), DHFR.ATF6 (TMP; 10 mM), or both. The metabolic-labeling protocol employed is shown.
(B) Quantification of autoradiograms as shown in (A). Fraction secreted was calculated as previously described by Sekijima et al. (2005). Error bars represent SE
from biological replicates (n = 4).
(legend continued on next page)
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Previously, small molecule TTR ligands including the endoge-
nous ligand thyroxine were shown to increase secretion of
destabilized TTR mutants, such as TTRA25T (Sekijima et al.,
2005). The thyroxine-dependent increase in mutant TTR secre-
tion is predicted to contribute to the deposition of highly destabi-
lized TTRmutants in the CNS (Sekijima et al., 2005). We explored
whether ATF6 activation could attenuate the ligand-dependent
increase in mutant TTR secretion using the highly selective small
molecule TTR stabilizer tafamidis (Bulawa et al., 2012). As ex-
pected, both pulse-chase experiments and quantitative immu-
noblotting show that the addition of tafamidis increases
FTTTRA25T secretion (Figures 5E, S4H, and S4I). ATF6 activation
attenuates this tafamidis-mediated increase in FTTTRA25T secre-
tion (Figures 5E, S4H, and S4I). Notably, tafamidis also attenu-
ates the ATF6-dependent increase in mutant TTR degradation
(cf. Figures 5D and S4I), suggesting that tafamidis stabilizes
FTTTRA25T in the ER lumen. These results indicate that ATF6 acti-
vation prevents the increase in mutant TTR secretion afforded by
ligand-dependent stabilization of the TTR tetramer.
To further explore the potential for ATF6 activation to decrease
mutant TTR secretion in a physiologically relevantmodel system,
we leveraged the high transportability (see Figure 1E) of our
methodology to activate ATF6 to establish a liver-derived
HepG2 cell line stably expressing DHFR.ATF6 (the liver produces
95% of the TTR in human serum). TMP-dependent activation of
DHFR.ATF6 inHepG2 cells was confirmed by qPCR (Figure S4J).
We overexpressed FTTTRA25T in these HepG2 cells, which
already secrete high levels of endogenous TTRWT. ATF6 activa-
tion reduced FTTTRA25T secretion by 35% in HepG2 cells but
did not affect secretion of endogenous TTRWT (Figures 5F and
S4K). Thus, ATF6 activation selectively reduces the secretion
of destabilized TTRmutants from physiologically relevant human
liver-derived cells.
We further explored the secretion of TTR heterotetramers
comprising TTRD18G subunits and TTRWT subunits from
HEK293DAX cells. Although TTRD18G is too destabilized to be
significantly secreted as a homotetramer (Figure S4F) (Hammar-
stro¨m et al., 2003a), the expression of both TTRD18G and TTRWT
enables heterotetramers composed of TTRD18G and TTRWT sub-
units to be secreted (Hammarstro¨m et al., 2003b; Sekijima et al.,
2005). Activating ATF6 in HEK293DAX cells expressing both
FTTTRD18G and TTRWT decreases the secretion of the amyloido-
genic FTTTRD18G subunit that is permitted by heterotetramer for-
mation (Figures 5G and S4L).(C) Graph depicting the normalized fraction secreted of [35S]-labeled FTTTRWT (w
DHFR.ATF6 (TMP; 10 mM) in HEK293DAX cells. Error bars represent SE from biol
(D) Graph depicting the total [35S]-labeled FTTTRA25T remaining in HEK293DAX cells
calculated as reported previously by Sekijima et al. (2005). Error bars represent
(E) Graph depicting the normalized fraction secreted of [35S]-labeled FTTTRA25T (o
the presence or absence of tafamidis (10 mM; 15 hr) in HEK293DAX cells. Error ba
(F) Bar graph depicting the normalized fraction secreted of FTTTRA25T and endoge
cells stably expressing DHFR.ATF6. Error bars represent SE from biological repl
(G) Bar graph depicting the normalized fraction secreted of [35S]-labeled FTTTRD18
transfected with both FTTTRD18G and TTRWT. Error bars represent SE from biolog
(H) Immunoblot of a-FLAGM1 FTTTRA25T immunoisolations fromDSP-crosslinke
activation of XBP1s (dox; 1 mg/ml), DHFR.ATF6 (TMP; 10 mM), or both. HEK293
immunoblot shows BiP.
*p < 0.05, **p < 0.01, ***p < 0.005. See also Figure S4.
CWe next explored the impact of ATF6 activation on the interac-
tions between FTTTRA25T and the central ER chaperone BiP,
which was previously shown to selectively bind destabilized
TTR variants and affect their ER proteostasis (So¨rgjerd et al.,
2006; Susuki et al., 2009). We found that activating ATF6 in-
creases the amount of BiP and the BiP cochaperone HYOU1
that coimmunoprecipitates with FTTTRA25T (Figure 5H). Notably,
the extent of HYOU1 associationwith FTTTRA25T following XBP1s
activation did not increase, despite XBP1s increasing HYOU1
protein levels (Table 1). These results suggest that the progres-
sion of FTTTRA25T through the ER proteostasis network is altered
by ATF6-dependent remodeling of the ER environment.
DISCUSSION
Herein, we establish methodology that allows for the orthogonal,
small molecule-mediated regulation of the UPR-associated
transcription factors XBP1s and/or ATF6 in the same cell inde-
pendent of stress. We employ our methodology to reveal the
molecular composition of the three distinct ER proteostasis envi-
ronments accessible by activating the XBP1s and/or ATF6 tran-
scriptional programs. Furthermore, we show that selectively acti-
vating XBP1s and/or ATF6 differentially influences the ER
partitioning of destabilized protein variants between folding and
trafficking versus degradation. Our results provide molecular in-
sights into how the XBP1s and/or ATF6 transcriptional programs
remodel the ER proteostasis environment and demonstrate the
potential to influence the ER proteostasis of destabilized protein
variants via physiologic levels of arm-selective UPR activation.
Our quantitative transcriptional and proteomic profiling of
HEK293DAX cells provides an experimentally validated, concep-
tual framework to identify specific ER proteins and/or pathways
that can be adapted to alter the fate of disease-associated ER
client proteins (Figure 3). Critical pathways directly responsible
for the partitioning of ER client proteins between folding and traf-
ficking versus degradation are differentially impacted by XBP1s
and/or ATF6 activation. For example, the levels of BiP and BiP
cochaperones, which are known to modulate folding versus
degradation decisions of client proteins in the ER lumen, are
differentially influenced by XBP1s and/or ATF6 activation (Fig-
ure 3) (Kampinga and Craig, 2010). Considering the importance
of BiP cochaperones in defining BiP function, these findings sug-
gest that the fates of BiP clients are distinctly influenced by
XBP1s and ATF6 activation. Consistent with this prediction, wehite bars) or FTTTRA25T (orange bars) at 4 hr following a 15 hr preactivation of
ogical replicates (n = 8 for FTTTRA25T, and n = 9 for FTTTRWT).
(combinedmedia and lysate protein levels as in A). The fraction remaining was
SE from biological replicates (n = 8).
range bars) at 4 hr following preactivation of DHFR.ATF6 (TMP; 10 mM; 15 hr) in
rs represent SE from biological replicates (n = 4).
nous TTRWT at 4 hr following a 13 hr pretreatment with TMP (100 mM) in HepG2
icates (n = 4).
G at 4 hr following a 15 hr pretreatment with TMP (10 mM) from HEK293DAX cells
ical replicates (n = 4).
d lysates prepared fromHEK293DAX cells expressing FTTTRA25T following 15 hr
DAX cells expressing GFP are shown as a negative control (Mock). The KDEL
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show that BiP and HYOU1 have increased association with
TTRA25T only when ATF6 is activated, even though HYOU1 is
also upregulated by XBP1s (Table 1).
Analogously, XBP1s- or ATF6-dependent remodeling of ER
client protein folding pathways can be deconvoluted from our
bioinformatic characterization of HEK293DAX cells. For example,
XBP1s-selective transcriptional upregulation of the ERAD-asso-
ciated proteins ERMan1, ERdj5, and EDEM-3 may explain the
enhanced degradation of NHK-A1AT upon XBP1s activation
because overexpression of these three proteins enhances
NHK-A1AT ERAD (Hosokawa et al., 2003, 2006; Ushioda et al.,
2008). Alternatively, ATF6 selectively enhances the expression
of the ERAD-associated protein Sel1L, which when overex-
pressed, accelerates degradation of the nonglycosylated protein
NHK-A1ATQQQ (Iida et al., 2011). Thus, our transcriptional and
proteomicprofilesof cells remodeledbyXBP1sand/orATF6acti-
vation enable hypothesis generation to dissect the contributions
of ER proteostasis proteins and/or pathways involved in altering
the folding, trafficking, or degradation of ER client proteins.
We used HEK293DAX cells to explore the potential for ER pro-
teostasis environments accessed through arm-selective UPR
activation to reduce the secretion of a destabilized, amyloido-
genic TTR variant. We found that ATF6 activation selectively re-
duces secretion of the destabilized, aggregation-prone TTRA25T,
but not the secretion of TTRWT or the global endogenous
secreted proteome. Previously, we and others have demon-
strated that the efficient secretion of destabilized TTR variants
through the hepatic secretory pathway is a contributing factor
to the extracellular aggregation and distal deposition of TTR as
amyloid in the pathology of numerous TTR amyloid diseases
(Hammarstro¨m et al., 2002, 2003a; Holmgren et al., 1993; Seki-
jima et al., 2003, 2005; Suhr et al., 2000; Susuki et al., 2009; Tan
et al., 1995). Thus, our discovery that ATF6-dependent remodel-
ing of the ER proteostasis environment selectively reduces
secretion of destabilized TTRA25T reveals a potential mechanism
to attenuate the secretion and subsequent pathologic extracel-
lular aggregation of the >100 destabilized TTR variants involved
in TTR amyloid diseases (Sekijima et al., 2008). Furthermore, the
establishment and characterization of the DHFR.ATF6 construct
(which we demonstrate can be rapidly incorporated into any
cellular model) and the HEK293DAX cell line provide invaluable re-
sources to evaluate the functional impact of arm-selective UPR
activation to physiologic levels on the aberrant ER proteostasis
of destabilized mutant proteins involved in the pathology of
many other protein misfolding-related diseases. Consistent
with the potential to correct pathologic imbalances in destabi-
lized protein ER proteostasis, recent studies that employ global
UPR activation using toxic small molecules or the unregulated
overexpression of XBP1s or ATF6 have suggested that remodel-
ing ER proteostasis pathways through arm-selective UPR acti-
vation could correct the aberrant ER proteostasis of pathologic
destabilized protein mutants involved in protein misfolding dis-
eases (Chiang et al., 2012; Mu et al., 2008; Smith et al., 2011a).
Finally, we note that despite clear functional roles for XBP1s
and ATF6 in adapting the composition of ER proteostasis path-
ways highlighted herein, organisms have distinct dependencies
on these transcription factors. XBP1s is critical for biological pro-
cesses including plasma cell differentiation and development1290 Cell Reports 3, 1279–1292, April 25, 2013 ª2013 The Authors(XBP1s knockoutmice are not viable; Reimold et al., 2000). Alter-
natively, mice lacking ATF6a, the primary ATF6 homolog
involved in UPR-dependent remodeling of the ER proteostasis
environment, develop normally, although deletion of both
mammalian ATF6 homologs, ATF6a and ATF6b, is embryonic le-
thal (Adachi et al., 2008; Wu et al., 2007; Yamamoto et al., 2007).
Thus, whereas XBP1s is required for organismal development,
our results suggest that functional roles for ATF6 in remodeling
the ER proteostasis environment are adaptive—adjusting ER
proteostasis capacity to match demand under conditions of
cellular or organismal stress. Therefore, modulation of ATF6
may provide a unique opportunity to sensitively ‘‘tune’’ the ER
proteostasis environment without globally influencing the
folding, trafficking, or degradation of the secreted proteome.
In summary, we show that the application of DD methodology
to control ATF6 transcriptional activity provides an experimental
strategy to characterize the impact of stress-independent acti-
vation of XBP1s and/or ATF6 on ER proteostasis pathway
composition and ER function. Adapting the underlying biology
of the proteostasis network through the activation of specific
UPR transcriptional programs reveals emergent functions of
the proteostasis network, including a window to alter the ER
proteostasis of destabilized mutant proteins without significantly
affecting the proteostasis of the vastmajority of the endogenous,
wild-type proteome. Our transcriptional, proteomic, and func-
tional characterization of the ER proteostasis environments
accessible by activating XBP1s and/or ATF6 in a single cell val-
idates targeting specific pathways within the proteostasis
network as a potential therapeutic approach for adapting the
aberrant ER proteostasis associated with numerous protein mis-
folding diseases, strongly motivating the development of arm-
selective small molecule activators of the UPR.
EXPERIMENTAL PROCEDURES
Plasmids
DHFR.YFP.pBMN was a generous gift from Professor T.J. Wandless at Stan-
ford University. ATF6 was amplified from human cDNA, substituted for YFP in
DHFR.YFP.pBMN between the SphI and NotI sites, and then transferred to
pENTR1A vectors using the BamH1 and Not1 sites. XBP1s was amplified
from human cDNA and cloned between the BamHI and Not1 sites in
pENTR1A. EGFP and ATF6were similarly cloned into empty pENTR1A vectors
using the BamHI and Not1 sites. Genes of interest in pENTR1A were shuttled
into pcDNA-DEST40, pT-REx-DEST30, pLenti4/TO/V5-DEST, or pAd/CMV/
V5-DEST vectors, as appropriate, using LR clonase II (Invitrogen) recombina-
tion. A1AT-NHK.pcDNA 3.1 was a generous gift from Professor R.R. Kopito at
Stanford University. FTTTRWTwas cloned from FTTTRWT.pET3C (Sekijima et al.,
2005) into pcDNAI using the BamHI and BstB1 sites. FTTTRA25T.pcDNAI and
A1AT-NHKQQQ.pcDNA3.1 were prepared by site-directed mutagenesis. All
constructs were sequenced to confirm their identity.
Immunoblotting
Postnuclear supernatants and nuclear lysates (prepared as described in the
Extended Experimental Procedures) were separated by SDS-PAGE and
analyzed by immunoblotting using the Li-COR Biosciences Odyssey System.
Details of immunoprecipitation experiments and antibodies used are provided
in the Extended Experimental Procedures.
Quantitative RT-PCR
The relative mRNA expression levels of target genes were measured using
quantitative RT-PCR (see the Extended Experimental Procedures for details
and Table S4 for a list of the primers used).
Cell Culture and Transfections
HEK293T-REx cells (Invitrogen) were cultured in complete DMEM (CellGro)
supplemented with 10% fetal bovine serum (FBS) (CellGro). Transient trans-
fections of DHFR.ATF6, ATF6, DHFR.YFP, EGFP, A1AT, and TTR constructs
were performed by calcium phosphate transfection. Lentiviruses encoding
dox-inducible XBP1s and EGFP were transduced into HEK293T-REx cells ex-
pressing DHFR.ATF6 or DHFR.YFP, respectively, using 1–5 ml of virus in media
containing 5 mg/ml polybrene. Adenoviruses encoding DHFR.ATF6 or
DHFR.YFP were transduced into HepG2, Huh7, and primary human fibro-
blasts at identical multiplicities of infections, experimentally determined to
transduce90% of cells. Detailed protocols for lentivirus and adenovirus pro-
duction are provided in the Extended Experimental Procedures. Stable cell
lines were selected by culturing in blasticidin (10 mg/ml), geneticin sulfate
(G-418; 500 mg/ml), or zeocin (50 mg/ml), as appropriate, prior to single-colony
selection and characterization.Whole-Genome Array Analyses
HEK293DAX or HEK293DYG cells were treated for 12 hr with vehicle, 1 mg/ml
dox, 10 mM TMP, or both in biological triplicate. Cells were harvested, and
RNA was extracted using the RNeasy Mini Kit (QIAGEN). Genomic DNA was
removed by on-column digestion using the RNase-free DNase Set (QIAGEN).
Detailed protocols for the whole-genome array analyses are provided in the
Extended Experimental Procedures. Data from HEK293DYG cells showed no
significant overlap in the ligand-treated transcriptomes obtained from
HEK293DAX and HEK293DYG cells (see Table S1).SILAC-Assisted Liquid Chromatography-Mass Spectrometry
Analyses
HEK293DAX cells were grown for >6 passages in either light or heavy SILAC
media (heavy media were supplemented with lysine,2HCl-[U-13C6, 97%–
99%] and arginine,2HCl [U-13C6, 99%, and U-
15N4, 99%]; Cambridge Iso-
topes). Samples were prepared from ‘‘heavy’’ HEK293DAX cells treated for
12 hr with dox (1 mg/ml), TMP (10 mM), or both and ‘‘light’’ cells treated with
vehicle. Detailed protocols for cell lysis and mass spectrometric analyses
are provided in the Extended Experimental Procedures.Pulse-Chase Experiments
HEK293DAX or HEK293DYG cells plated on poly-D-lysine-coated plates were
metabolically labeled in pulse medium ([35S]-Translabel [MP Biomedical],
DMEMCys/Met [CellGro] with supplemented glutamine, penicillin/strepto-
mycin, and dialyzed FBS) for 30 min. Cells were then washed with complete
media and incubated in prewarmed DMEM for the indicated chase times. Me-
dia or lysates were harvested at the indicated times. Lysates were prepared in
either 20 mM HEPES (pH 7.5), 100 mM NaCl, 1% Triton X-100, and fresh pro-
tease inhibitor cocktail (Roche) for NHK-A1AT experiments or standard RIPA
buffer for TTR experiments. Proteins were immunopurified using either anti-
HA antibody conjugated to protein-G Sepharose or M1 anti-Flag beads
(Sigma-Aldrich), respectively. The resin was eluted by boiling beads in Laemili
buffer, and the samples were separated by SDS-PAGE. The gels were then
dried, exposed to phosphorimager plates (GE Healthcare), and imaged with
a Typhoon imager. Band intensities were quantified by densitometry in
ImageQuant.ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the data reported herein
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